Earnings ·
Rigel Pharmaceuticals reported second quarter 2026 total revenues of $78.7 million and net income of $17.3 million, or…
RIGLRigel Pharmaceuticals Inc
Rigel Pharmaceuticals reported second quarter 2026 total revenues of $78.7 million and net income of $17.3 million, or $0.93 basic per share. Net product sales reached $67.0 million, driven by TAVALISSE ($47.4 million), GAVRETO ($10.7 million), and REZLIDHIA ($8.9 million). The company raised its full-year 2026 revenue guidance to approximately $285–$295 million. Rigel also announced the in-license of VEPPANU (vepdegestrant) from Arvinas and Pfizer, paying a $70.0 million upfront fee, with commercial availability expected in mid-August 2026. Additionally, Rigel appointed Alison L. Hannah as Executive Vice President and Chief Medical Officer. The company operates in the biotechnology industry, focusing on discovering and developing therapies for hematologic disorders and cancer.